Michael Schrag
Micropharma (Canada)(CA)
Publications by Year
Research Areas
Pharmacogenetics and Drug Metabolism, Drug Transport and Resistance Mechanisms, Cholangiocarcinoma and Gallbladder Cancer Studies, Analytical Chemistry and Chromatography, Sphingolipid Metabolism and Signaling
Most-Cited Works
- → Hematopoietic Progenitors and Aging: Alterations in Granulocytic Precursors and Responsiveness to Recombinant Human G-CSF, GM-CSF, and IL-3(1993)140 cited
- → Discovery and Optimization of a Series of Benzothiazole Phosphoinositide 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Dual Inhibitors(2011)119 cited
- → MECHANISM-BASED INHIBITION OF HUMAN LIVER MICROSOMAL CYTOCHROME P450 1A2 BY ZILEUTON, A 5-LIPOXYGENASE INHIBITOR(2003)105 cited
- → A Refined 3-Dimensional QSAR of Cytochrome P450 2C9: Computational Predictions of Drug Interactions(2000)91 cited
- → Pyrene·Pyrene Complexes at the Active Site of Cytochrome P450 3A4: Evidence for a Multiple Substrate Binding Site(2002)90 cited
- → Covalent Alteration of the CYP3A4 Active Site: Evidence for Multiple Substrate Binding Domains(2001)76 cited
- → Naphthamides as Novel and Potent Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors: Design, Synthesis, and Evaluation(2008)70 cited
- → SULFOTRANSFERASE 1E1 IS A LOW KM ISOFORM MEDIATING THE 3-O-SULFATION OF ETHINYL ESTRADIOL(2004)65 cited
- → Triazolam Substrate Inhibition(2001)61 cited
- → Discovery of AMG 369, a Thiazolo[5,4-b]pyridine Agonist of S1P1 and S1P5(2010)54 cited